Celcuity Inc. CELC
We take great care to ensure that the data presented and summarized in this overview for Celcuity Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CELC
View all-
Perceptive Advisors LLC New York, NY2.36MShares$39.6 Million1.07% of portfolio
-
Morgan Stanley New York, NY2.35MShares$39.4 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.73MShares$29 Million3.06% of portfolio
-
Commodore Capital LP New York, NY1.56MShares$26.1 Million2.9% of portfolio
-
Baker Bros. Advisors LP New York, NY1.55MShares$26 Million0.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA1.39MShares$23.3 Million0.48% of portfolio
-
Nea Management Company, LLC Timonium, MD1.25MShares$21 Million1.89% of portfolio
-
Black Rock Inc. New York, NY1.11MShares$18.6 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY970KShares$16.3 Million1.8% of portfolio
-
Balyasny Asset Management LLC Chicago, IL882KShares$14.8 Million0.03% of portfolio
Latest Institutional Activity in CELC
Top Purchases
Top Sells
About CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at CELC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 26
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
45,025
+4.72%
|
-
|
|
Apr 26
2024
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
45,025
-3.76%
|
-
|
|
Apr 24
2024
|
Richard E Buller Director |
SELL
Open market or private sale
|
Direct |
350
-4.33%
|
$5,950
$17.06 P/Share
|
|
Mar 18
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
765,897
+50.0%
|
-
|
|
Mar 18
2024
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
765,897
-80.2%
|
-
|
|
Feb 21
2024
|
Richard E Buller Director |
SELL
Open market or private sale
|
Direct |
350
-4.15%
|
$4,900
$14.15 P/Share
|
|
Jan 30
2024
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
85,000
+8.17%
|
-
|
|
Jan 30
2024
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
85,000
-6.62%
|
-
|
|
Dec 27
2023
|
Brian F. Sullivan Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
1,733,347
+50.0%
|
-
|
|
Dec 27
2023
|
Brian F. Sullivan Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,733,347
-57.46%
|
-
|
|
Dec 20
2023
|
Richard E Buller Director |
SELL
Open market or private sale
|
Direct |
350
-3.99%
|
$4,900
$14.37 P/Share
|
|
Dec 15
2023
|
David Dalvey Director |
SELL
Open market or private sale
|
Indirect |
2,940
-1.29%
|
$41,160
$14.57 P/Share
|
|
Dec 14
2023
|
David Dalvey Director |
SELL
Open market or private sale
|
Indirect |
5,000
-2.15%
|
$70,000
$14.75 P/Share
|
|
Dec 13
2023
|
David Dalvey Director |
SELL
Open market or private sale
|
Indirect |
5,000
-2.1%
|
$70,000
$14.5 P/Share
|
|
Dec 12
2023
|
David Dalvey Director |
SELL
Open market or private sale
|
Indirect |
2,060
-0.86%
|
$28,840
$14.61 P/Share
|
|
Dec 08
2023
|
David Dalvey Director |
SELL
Open market or private sale
|
Indirect |
5,000
-2.04%
|
$75,000
$15.0 P/Share
|
|
Dec 07
2023
|
David Dalvey Director |
SELL
Open market or private sale
|
Indirect |
5,000
-2.0%
|
$70,000
$14.85 P/Share
|
|
Nov 28
2023
|
Leo Furcht Director |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+2.33%
|
$250
$1.6 P/Share
|
|
Oct 25
2023
|
Richard E Buller Director |
SELL
Open market or private sale
|
Direct |
350
-3.83%
|
$3,500
$10.23 P/Share
|
|
Aug 30
2023
|
Richard E Buller Director |
SELL
Open market or private sale
|
Direct |
350
-3.69%
|
$3,150
$9.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.96K shares |
|---|---|
| Bona fide gift | 2.63M shares |
| Exercise of conversion of derivative security | 250 shares |
| Open market or private purchase | 10K shares |
| Open market or private sale | 27.8K shares |
|---|---|
| Bona fide gift | 2.63M shares |